Many noninvasive methods for diagnosing liver fibrosis (LF) have been proposed. To determine the best method for diagnosing LF in nonalcoholic fatty liver disease (NAFLD), we conducted a systemic review and meta-analysis to compare the performance of aspartate aminotransferase to platelets ratio index (APRI), fibrosis-4 index (FIB-4), BARD score, NAFLD fibrosis score (NFS), FibroScan, shear wave elastography (SWE), and magnetic resonance elastography (MRE) for diagnosing LF in NAFLD. We compared the sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve (AUROC) of these noninvasive methods for detecting significant fibrosis (SF), advanced fibrosis (AF), and cirrhosis. Heterogeneity was explored using meta-regression. Sixty-four articles with a total of 13,046 NAFLD subjects were included. The overall mean prevalence of SF, AF, and cirrhosis was 45.0%, 24.0%, and 9.4% in NAFLD patients, respectively. With an APRI threshold of 1.0 and 1.5, the sensitivities and specificities were 50.0% and 84.0% and 18.3% and 96.1%, respectively, for AF. With a FIB-4 threshold of 2.67 and 3.25, the sensitivities and specificities were 26.6% and 96.5% and 31.8% and 96.0%, respectively, for AF. The summary sensitivities and specificities of BARD score (threshold of 2), NFS (threshold of 21.455), FibroScan M (threshold of 8.7-9), SWE, and MRE for detecting AF were 0.76 and 0.61, 0.72 and 0.70, 0.87 and 0.79, 0.90 and 0.93, and 0.84 and 0.90, respectively. The summary AUROC values using APRI, FIB-4, BARD score, NFS, FibroScan M probe, XL probe, SWE, and MRE for diagnosing AF were 0. 77, 0.84, 0.76, 0.84, 0.88, 0.85, 0.95, and 0.96, respectively. Conclusion: MRE and SWE may have the highest diagnostic accuracy for staging fibrosis in NAFLD patients. Among the four noninvasive simple indexes, NFS and FIB-4 probably offer the best diagnostic performance for detecting AF. (HEPATOLOGY 2017;66:1486-1501.
N onalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases. (1) In both adults and children, its incidence is rising continuously because of the increasing prevalence of obesity and type 2 diabetes. (2, 3) A proportion of patients with NAFLD will have progressive liver fibrosis (LF). (2) Liver biopsy, the gold standard for the assessment of LF, is a costly procedure with risk of severe complications. It also exhibits intrinsic sampling variability Abbreviations: AF, advanced fibrosis; APRI, aspartate aminotransferase to platelets ratio index; AUROC, area under the receiver operating characteristic curve; DOR, diagnostic odds ratio; FIB-4, fibrosis-4 index; HBV, hepatitis B virus; HCV, hepatitis C virus; LF, liver fibrosis; LR, likelihood ratio; MRE, magnetic resonance elastography; NAFLD, nonalcoholic fatty liver disease; NFS, NAFLD score; NPV, negative predictive value; PPV, positive predictive value; QUADAS, Quality Assessment of Diagnostic Accuracy Studies; ROC, receiver operating characteristic; SF, significant fibrosis; SWE, shear wave elastography.
because of the small sample size and the restriction of the biopsy area relative to the whole liver. (4) Moreover, it is unacceptable to patients to use biopsy as a means of long-term dynamic monitoring of LF stages. Therefore, the development of reliable noninvasive methods for the assessment of LF has become essential to estimate the progression of the disease and to guide therapy.
Dozens of noninvasive models composed of blood biochemical biomarkers have been proposed to detect LF, including aspartate aminotransferase to platelets ratio index (APRI) (5) and fibrosis-4 index (FIB-4). (6) However, APRI and FIB-4 were established based on patients with hepatitis C virus (HCV) infection or HIV/HCV coinfection. Our previous study indicated that the accuracy of these two models in the diagnosis of LF induced by hepatitis B virus (HBV) was not satisfactory. (7) Therefore, researchers have proposed specific models for detecting LF caused by various etiologies, such as NAFLD score (NFS) (8) and BARD score (9) for NAFLD. Nevertheless, the diagnostic value of these models consisting of simple metrics remains debated. Elastography, an imaging method, has been shown to be a reliable method to diagnose fibrosis. (10) (11) (12) A recent study of 142 NAFLD patients showed that magnetic resonance elastography (MRE) had higher diagnostic performance in the detection of fibrosis than transient elastography (FibroScan) and simple blood models. (13) However, the study included a relatively small sample size, and it did not investigate the clinical usefulness of FibroScan XL probe and realtime shear wave elastography (SWE).
Therefore, the purpose of our study was to conduct a systemic review and meta-analysis to compare the diagnostic accuracy of APRI, FIB-4, BARD score, NFS, FibroScan M probe, FibroScan XL probe, SWE, and MRE for the assessment of LF in patients with NAFLD. The aim of this analysis was to obtain the most accurate and optimal noninvasive methods for staging hepatic fibrosis in NAFLD.
Materials and Methods

LITERATURE SEARCH STRATEGY
We developed our search strategy in collaboration with an experienced research librarian (Mei Wang). The search strategy is provided in Supporting Table 1 . The searches were performed in PubMed/MED-LINE, Ovid/EMBASE, the Web of Science, and the Cochrane Library using the following search terms: nonalcoholic fatty liver disease, liver fibrosis, APRI, FIB-4, NAFLD fibrosis score, BARD score, FibroScan, transient elastography, shear wave elastography, and magnetic resonance elastography. In addition, we used OpenSIGLE to search for gray literature. Moreover, the bibliographic reference lists of the relevant articles were manually searched. We limited our search to the literature published before February 2017.
INCLUSION AND EXCLUSION CRITERIA
The original research articles were included if they fulfilled the following criteria: 1) the study evaluated the performance of APRI, FIB-4, BARD score, NFS, FibroScan, SWE, or MRE for staging fibrosis in NAFLD patients; 2) pathological examination was used as the reference for assessing fibrosis; 3) the study included more than 20 NAFLD patients; and 4) the study with data to allow the construction of at least one 2 3 2 table for test performance. Reviews, book chapters, conference abstracts, patents, guidelines, protocols, and commentary were excluded. The articles containing animal or cellular experiments were also excluded. The studies written in languages other than
ARTICLE INFORMATION:
English or published in a non-SCI journal were excluded.
DEFINITION OF LIVER FIBROSIS
Significant fibrosis (SF), advanced fibrosis (AF), and cirrhosis were defined as stages F2-F4, F3-F4, and F4 using the Brunt & Kleiner, Metavir, Ludwig, or SAF scoring system.
DATA EXTRACTION AND QUALITY ASSESSMENT
Two investigators independently searched the databases, read the articles, and selected articles to include in the analysis. Both investigators independently checked the study eligibility and quality. The two researchers extracted data separately using a standardized, predesigned extraction form in Microsoft Excel 2007. The patients' data (including the total number of patients, mean age, sex, and the number of patients with different stages of LF) and the performance indices of different diagnostic methods (cutoff values, sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV] , and receiver operating characteristic [ROC] values) were extracted from each included article. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) score was used to assess the quality of the included studies. The discrepancies between the two investigator were submitted to a third investigator for examination. Finally, the discrepancies were resolved through a discussion among these three authors. In the three steps (searching literature, excluding and including articles, extracting data from the included studies) separately performed by the initial two investigators, the consistent item was recorded as having a score of 1, and the inconsistent item was recorded as having a score of 0. The number of items with a score of 1 was divided by the number of total items (with score 0 and score 1), yielding the concordance rate. The concordance rate between the two investigators was 94.8%.
DATA ANALYSIS
SPSS version 17.0, Review Manager version 5.2, and Meta-Disc version 1.4 were selected to analyze the tests for sensitivity, specificity, PPV, NPV, the summary area under the ROC curve (AUROC), positive likelihood ratio (LR), and negative LR. The forest plots and meta-regression analysis were performed using Stata version 12.0.
EVALUATION OF DIAGNOSTIC ACCURACY
The number of true positives, false positives, false negatives, and true negatives was extracted to construct the 2 3 2 tables. The summary PPV, NPV, positive LR, and negative LR values for each reported test cutoff were calculated. The summary AUROC, the summary diagnostic odds ratios (DORs), and the summary sensitivities and specificities were used to examine the diagnostic accuracy of the noninvasive methods included in our review for detecting SF, AF, and cirrhosis. The data from different studies were used simultaneously to construct the summary ROC curves to compare the summary AUROC values of these noninvasive methods for distinguishing different stages of fibrosis. Because the summary ROC curve only represents the relationship between the sensitivity and specificity values across studies with different thresholds for each method, the summary DORs were calculated using a Der-Simonian and Laird random effects model with a corresponding test of heterogeneity.
ASSESSMENT OF HETEROGENEITY AND PUBLICATION BIAS
The meta-analysis of factors was conducted based on a random-effects model, and the meta-regression was performed to explore the potential covariates that may induce heterogeneity for the diagnostic accuracy of each noninvasive method between studies using the Q-I 2 statistic. An I 2 value >50% or I 2 value > 25% with a P value < 0.01 may be considered to represent substantial heterogeneity. We further conducted a linear regression analysis of funnel plot asymmetry using a Deeks plot to examine the possible publication bias of the studies for the performance of each noninvasive method in staging hepatic fibrosis.
Results
CHARACTERISTICS OF THE RETRIEVED STUDIES
A total of 2689 records were retrieved using our search method. After removing duplications, 1327 records were retained. After excluding abstracts, reviews, non-English studies, non-SCI studies, and so forth, 223 full-text articles were downloaded for careful screening. By reading the full text, 64 studies were ultimately reserved for evaluation and meta-analysis (The 64 included studies as references are shown in the Supporting Information). The specific details of the excluded records are shown in Figure 1A . Table 1 provides the main features of the studies included in this review. Figure 1B1 shows that 27 (42.2%) studies were published between 2014 and 2016. Most of the included studies were from North America (13, 20 .3%), Europe (25, 39.1%), and Asia (22, 34.4%). In addition to 39 (60.9%) single-center studies, 22 (34.4%) studies included subjects from at least two centers. Among the included studies, there were 22 retrospective studies, 21 prospective studies, and one randomized controlled study. The distribution of journal impact factor is shown in Figure 1B5 . According to the QUADAS score, 5 (7.8%), 16 (25%), 23 (35.9%), and 20 (31.3%) studies scored 11, 12, 13, and 14 points, respectively, as shown in Figure 1B6 .
PATIENT CHARACTERISTICS
In total, 15,515 subjects were included. After the removal of other etiologies, 13,294 patients (13, 046 with NAFLD, 203 with viral hepatitis and 45 with other diseases) were selected for analysis. In two studies, the data of the patients with different etiologies (NAFLD, HBV, and other causes) were assembled for analysis. (14, 15) Male patients accounted for approximately 54.0% (19%-85.7%) of all patients. The mean age of the patients was 46.6 years. The subjects of five studies were minors (554 patients). In 28 studies, the patients' mean age was greater than 50 years (Supporting Information). Table 1 and Figure 2 show the distribution of the stages of fibrosis in NAFLD patients. The overall prevalence of SF, AF, and cirrhosis was 45.0% (15.0%-88.9%), 24.0% (3.9%-53.8%), and 9.4% (0%-33.3%), respectively. The mean percentages of fibrosis stages F0-F1, F2, F3, and F4 were 55.6%, 19.3%, 15.7%, and 9.4%, respectively. In children, the average incidences of SF and AF were 40% and 19.6%, respectively. In studies with patients whose mean ages were greater than 50 years, the prevalence of SF, AF, and cirrhosis were 45.8% (27.5%-73.1%), 29.1% (16.1%-53.8%), and 11% (0%-26%), respectively. Then, we compared the incidence of fibrosis in minors and patients with mean ages greater than 50 years and found that there was no significant difference in SF (P 5 0.73) and AF (P 5 0.24).
THE PREVALENCE OF FIBROSIS IN NAFLD
DETECTING SF
Thirty studies (with 4619 NAFLD patients) investigated these seven noninvasive methods for the prediction of SF (stage F2-F4). In these studies, 11 (2352 patients), 12 (2,330 patients), 5 (1330 patients), 11 (2098 patients), 16 (2354 patients), 3 (318 patients), 2 (233 patients), and 3 (384 patients) items addressed the APRI, FIB-4, BARD score, NFS, FibroScan M probe, FibroScan XL probe, SWE, and MRE, respectively for diagnosing SF. Table 2 shows that the summary sensitivities of APRI, FIB-4, BARD score, NFS, FibroScan XL probe, SWE, and MRE for detecting SF were 59.7%, 64.8%, 44.3%, 66.8%, 74.4%, 85.5%, and 77.7%, respectively. The summary specificities of APRI, FIB-4, BARD score, NFS, FibroScan XL probe, SWE, and MRE for detecting SF were 78.9%, 72.9%, 70.4%, 87.5%, 64.6%, 89.4%, and 91.5%, respectively. FibroScan M probe had summary sensitivity and specificity values of 91.9% and 55.5%, respectively, at a cutoff value of 5.8 kpa. The summary sensitivities and specificities of 10 studies were 80.1% and 68.3%, respectively, when FibroScan M probe was used to detect SF with cutoff values of 6.65-7 kpa. SWE had the highest summary PPV value of 92.2%, and FibroScan M probe (cutoff value 5 5.8 kpa) had the highest summary NPV value of 91.9% (Table 2) . MRE had the highest summary positive LR, with a value of 7.92.
At least three records are needed to estimate the summary AUROC values. The summary AUROC value of MRE (0.92) was significantly higher than that of the APRI (0.76, P 5 0.05), FIB-4 (0.73, P < 0.01), FibroScan M probe (0.82, P < 0.01), and XL probe (0.80, P < 0.01) for the diagnosis of SF. It showed that the FibroScan M probe had a higher AUROC value than FIB-4 with a P value of 0.05, as shown in Figure 3A . Table 3 shows that SWE and MRE had the highest mean AUROC values of 0.89 (range, 0.85-0.92) and 0.88 (range, 0.86-0.89), respectively, for predicting SF. A forest plot cannot be established unless there are more than four sets of data. In Figure  4A , we found that the summary DORs of the APRI, FIB-4, FibroScan M probe, and XL probe were Abbreviations: QUADAS, Quality Assessment of Studies of Diagnostic Accuracy Studies; RCT, randomized controlled trial.
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5.6 (I 2 5 84%, P < 0.01), 4.7 (I 2 5 79%, P < 0.01), 10.1 (I 2 5 0, P 5 0.59), and 7.1 (I 2 5 4.8%, P 5 0.37), respectively, for diagnosing SF.
DETECTING AF
Fifty-nine studies (12,558 patients) addressed the use of these seven noninvasive methods for predicting AF (stage F3-F4). Approximately 30 (6877 patients), 34 (8245 patients), 30 (7791 patients), 39 (9392 patients), 17 (2642 patients), 3 (318 patients), 3 (429 patients), and 6 (628 patients) studies examined APRI, FIB-4, BARD score, NFS, FibroScan M probe, FibroScan XL probe, SWE, and MRE in the diagnosis of AF. Table 2 shows that the summary sensitivities exceeded 80% when the FibroScan M probe, SWE, and MRE were used for detecting AD. The summary specificities of the six models (APRI, FIB-4, NFS, FibroScan M probe, SWE, and MRE) were greater than 85% for predicting AF. When APRI and FIB-4 were used to detect AF, their corresponding summary specificities were greater than 95%. The summary specificities of APRI (cutoff of 1.5), FIB-4 (cutoff of 2.67), BARD score (cutoff of 2), and NFS (cutoff of 0.67-0.676) were 96.1%, 96.5%, 61.3%, and 94.6%, respectively. Only FIB-4, NFS, FibroScan M probe, SWE, and MRE had a summary PPV greater than 70%. The NPV values of all methods were greater than 75% for the diagnosis of AF. The NPV of the FibroScan M probe was the highest (96.4%), with a cutoff value of 7.6-8 kpa.
In descending order, the summary AUROC values of these noninvasive methods for detecting AF were 0.96 (MRE), 0.95 (SWE), 0.88 (FibroScan M probe), 0.85 (FibroScan XL probe), 0.84 (FIB-4), 0.84 (NFS), 0.77 (APRI), and 0.76 (BARD score). Figure 3B shows that the summary AUROC values of SWE and MRE were significantly higher than others (all P values < 0.01). The AUROC value of FibroScan M Abbreviations: AF, advanced fibrosis; APRI, aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis-4 index; MRE, magnetic resonance elastography; NAFLD, nonalcoholic fatty liver disease; NPV, negative predictive value; PPV, positive predictive value; SF, significant fibrosis; SWE, shear wave elastography.
probe was significantly higher than those of APRI (P < 0.01), FIB-4 (P 5 0.02), BARD score (P < 0.01) and NFS (P 5 0.02). There was no significant difference between FibroScan M probe and XL probe (P 5 0.07) for the diagnosis of AF. Among the four blood models, FIB-4 and NFS had the largest summary AUROC values (0.84) for diagnosing AF. Table 3 shows that the mean AUROC values of SWE and MRE were 0.91 (range: 0.88-0.95) and 0.93 (range: 0.89-0.96), respectively. Figure 4B shows that the summary DORs of APRI, FIB-4, BARD score, NFS, FibroScan M probe and MRE were 5.7 (I 2 5 14%, P 5 0.29), 12.4 (I 2 5 48%, P < 0.01), 5.6 (I 2 5 49%, P < 0.01), 12.7 (I 2 5 64%, P < 0.01), 20.6 (I 2 5 40%, P 5 0.04) and 57.0 (I 2 5 51%, P 5 0.11), respectively, for predicting AF.
DETECTING CIRRHOSIS
Twenty-three studies examined the performance of these noninvasive methods for predicting cirrhosis (stage F4). There were 12 studies (2327 patients) about APRI, 8 studies (1872 patients) about FIB-4, 5 studies (1263 patients) about BARD score, 8 studies (1830 patients) about NFS, 13 studies (1780 patients) about FibroScan M probe, 3 studies (318 patients) about FibroScan XL probe, 1 study (181 patients) about SWE, and 3 studies (384 patients) about MRE. Table 2 shows that the summary sensitivities of APRI, FIB-4, BARD score, NFS, FibroScan XL probe, SWE, and MRE for detecting cirrhosis were 63.5%, 77.4%, 52.2%, 80.0%, 84.6%, 100% and 86.7%, respectively. The summary specificities of APRI, FIB-4, BARD score, NFS, FibroScan XL probe, SWE and MRE for predicting cirrhosis were 78.1%, 83.2%, 83.8%, 80.8%, 80.6%, 85.6%, and 93.5%, respectively. FibroScan M probe had summary sensitivity and specificity values of 86.7% and 86.0%, respectively, at cutoff values of 10.3-11.3 kpa. FibroScan M probe, SWE, and MRE showed summary PPV values greater than 50%. The summary NPV values of all methods were greater than 90% for predicting cirrhosis. MRE had the highest summary positive LR, with a value of 13.1. Figure 3C shows that the summary AUROC values of APRI, FibroScan M probe, FibroScan XL probe, and MRE were 0.76, 0.94, 0.91, and 0.97, respectively, for the diagnosis of cirrhosis. In descending (Table 3 ). Figure 4C showed that the summary DORs of APRI and FibroScan M probe were 7.3 (I 2 5 11%, P 5 0.35), and 44.0 (I 2 5 0, P 5 0.48), respectively, for diagnosing cirrhosis.
HETEROGENEITY AND PUBLICATION BIAS
A meta-regression analysis only can be conducted in groups of more than 10 studies with complete data for examining the methodological heterogeneity. In groups larger than 10 studies, heterogeneity existed when FIB-4, BARD score, NFS, and FibroScan M probe were used for detecting AF. The diagnostic accuracy was not affected by the following factors when FIB-4, BARD score, NFS, and FibroScan M probe were used to diagnose AF: the location of the study (P 5 0.73, 0.15, 0.25, and 0.54), study design (P 5 0.14, 0.06, 0. The linear regression test of funnel plot asymmetry can be established with more than two sets of data. Abbreviations: AF, advanced fibrosis; APRI, aspartate aminotransferase to platelet ratio index; AUC, area under the curve; FIB-4, fibrosis-4 index; MRE, magnetic resonance elastography; NAFLD, nonalcoholic fatty liver disease; SF, significant fibrosis; SWE, shear wave elastography. There was publication bias for MRE for detecting AF with P 5 0.04 (Fig. 5B ) and for FibroScan for predicting cirrhosis with P 5 0.01 (Fig. 5C ). Figure 5 shows that there was no evidence of publication bias for other methods for the diagnosis of SF, AF, and cirrhosis.
Discussion
In this study, we conducted a systematic review and meta-analysis, which included 64 (13,046 NAFLD patients) original articles with enough data to investigate the diagnostic performance of APRI, FIB-4, BARD score, NFS, FibroScan (M probe and XL probe), SWE, and MRE for predicting SF, AF, or cirrhosis in patients with NAFLD.
Before assessing the diagnostic ability of new methods for detecting hepatic fibrosis in NAFLD patients, we should understand the prevalence of fibrosis among this particular population. Our results showed that the overall mean prevalence of SF, AF, and cirrhosis was 45.0%, 24.0%, and 9.4%, respectively, in NAFLD patients. It has been reported that the mean incidence of SF, AF and cirrhosis was 56.6%, 33.5%, and 18.4% in patients with HBV infection, and the incidence of SF, AF, and cirrhosis was 57%, 35%, and 13% in HCV-infected patients. (7, 16) This suggests that the incidence of fibrosis may be lower in NAFLD than in HBV-or HCV-infected patients.
Among the noninvasive methods in this review, the NFS and the FIB-4 score include age in their models. Some researchers suggest that the incidence of fibrosis lacks an association with age in patients with HCV infection. (17) However, McPherson et al. (18) reported that the occurrence rate of AF (stages 3-4) was higher in patients who were over 56 years of age and demonstrated that the ROC values of FIB-4 and NFS were greater than those of aspartate aminotransferase to alanine aminotransferase ratio for predicting fibrosis in NAFLD patients of different ages. However, the authors also reported that the specificity of the aspartate aminotransferase to alanine aminotransferase ratio for detecting AF decreases with increasing age.
In the prediction of SF and cirrhosis, the summary AUROC of MRE (0.92 and 0.97), FibroScan M probe (0.82 and 0.94), XL probe (0.80 and 0.91), APRI (0.76 and 0.76), and FIB-4 (0.73 for SF) progressively decreased (Fig. 3A,C) . We found that MRE and FibroScan had higher AUROC values when they were used for the diagnosis of cirrhosis than for the diagnosis of SF. In addition, the summary mean sensitivities and specificities of MRE and FibroScan for the prediction of cirrhosis were also greater than those for the prediction of SF. This suggests that MRE and FibroScan are more accurate in detecting cirrhosis than detecting SF.
The results demonstrated that the summary AUROC value of MRE was significantly greater than those of APRI (P 5 0.05), FIB-4 (P < 0.01), FibroScan M probe (P < 0.01), and XL probe (P < 0.01). Additionally, the AUROC of MRE was significantly higher than those for APRI (P 5 0.03) and FibroScan M probe (P 5 0.01). This implies that MRE offered the best diagnostic performance in the diagnosis of SF and cirrhosis. Several studies also demonstrate that MRE is superior to transient elastography and noninvasive indexes for the diagnosis of liver fibrosis in patients with NAFLD. (19) (20) (21) (22) Most of the included articles reported data on detecting AF, and thus, we can compare the diagnostic accuracy of all noninvasive methods for the prediction of AF. The results showed that the summary AUROC values of SWE (0.95) and MRE (0.96) were significantly greater than others, with all P values < 0.01. This finding suggests that MRE and SWE are reliable for the evaluation of liver fibrosis. Imajo et al. (13) demonstrated that MRE has a greater diagnostic performance in the detection of fibrosis in patients with NAFLD than FibroScan, APRI, FIB-4, BARD score and NFS. Ochi and colleagues (23) compared the diagnostic effects of SWE with FIB-4, BARD score and NFS, and they suggest that SWE is useful in evaluating hepatic fibrosis. In addition, our results indicated that the AUROC of FibroScan M probe for diagnosing AF was significantly higher than those of APRI, FIB-4, BARD score and NFS. Some investigators have discussed the possible reasons why MRE is more accurate than FibroScan for staging fibrosis and its advantages. (13, 24) In our previous meta-analysis, we showed that the summary AUROC values of APRI and FIB-4 for the diagnosis of SF, AF, and cirrhosis are 0.74 and 0.78, 0.73 and 0.82, and 0.73 and 0.84, respectively, in adult patients with HBV infection.
(7) Afdhal et al. (25) demonstrate that in patients with HBV or HCV infection the AUROC values of FibroScan for diagnosis of SF and cirrhosis are 0.89 and 0.92, respectively. In a prospective study with HBV-or HCV-infected patients, the investigators indicate that the AUROC of MRE for predicting SF, AF, and cirrhosis are 0.96, 0.98, and 0.98, respectively. (26) Compared with the present study, it suggests that in NAFLD, the diagnostic accuracy of APRI, FIB-4, Fibroscan and MRE is similar to that in HBV-or HCV-infected individuals (Fig. 3) . We acknowledge that our study has some limitations. First, this systemic review and meta-analysis only focused on the full articles published with English in SCI Journals. Second, because of the insufficient data, we did not compare the diagnostic accuracy of these noninvasive models in children (27) (28) (29) (30) (31) with that of adults for predicting LF. These four articles (27) (28) (29) (30) did not report values of true positive, true negative, false positive, and false negative, so they were not selected into ROC analysis. Machado and colleagues (29) indicated that the noninvasive models developed in adults have poor performance for detecting fibrosis in children with NAFLD. Third, we did not consider the confounding factors of obesity and ascites. When ultrasound is used for examining the abdominal viscera, the abdominal fat thickness and ascites can lead to a sound distortion artifact and bias the results. Fourth, this study only involved hepatic fibrosis without considering the degree of hepatic steatosis. The different degrees of steatosis in NAFLD patients can interfere with the accuracy of MRE and ultrasound for the diagnosis of fibrosis. Furthermore, in the included studies, it is unknown how long each individual has endured NAFLD and whether or not they ever received treatment. These factors may impact the incidence and severity of liver fibrosis. In addition, our study did not consider the convenience of examination, the time and cost of inspection, and the issue of radiation. Theoretically, simple indexes are more convenient and less time consuming. Moreover, because few studies have discussed the financial cost, we cannot conduct a meta-analysis to compare which noninvasive method is the most expensive and which one cost the least. An original study showed that the NFS cost less in the evaluation of fibrosis in patients with NAFLD compared with FibroScan. (32) Imajo et al. (13) indicated that although the costs associated with the use of MRE are higher than those for FibroScan, MRE has the ability to scan the whole liver for screening other diseases. Besides that, each set of studies on the use of the FibroScan XL probe, SWE, and MRE for the diagnosis of hepatic fibrosis contained no more than five individual articles. The number of subjects who underwent MRE or SWE for predicting fibrosis was relatively small. Publication bias for MRE in detecting AF (P 5 0.04) and for FibroScan XL in diagnosing cirrhosis (P 5 0.01) was observed (Fig. 5) . This may limit the persuasiveness of the results. Finally, our metaanalysis of diagnostic studies maybe have the intrinsic limitations, including overestimation or underestimation of diagnostic accuracy due to spectrum bias, likely double-counting in multiple cohorts, selective reporting bias, inability to identify optimal thresholds, and possibly existing heterogeneity.
In conclusion, the incidence of hepatic fibrosis in NAFLD is slightly lower than that in chronic HBVor HCV-infected patients. MRE and SWE may have the highest diagnostic accuracy for staging fibrosis. Although the FibroScan M probe only has moderate accuracy for the diagnosis of AF, its performance may be superior to the noninvasive models that consist of simple indicators. Among the four noninvasive simple indexes, NFS and FIB-4 probably offer the best diagnostic performance for detecting AF. Additional prospective randomized controlled trials are needed to compare the diagnostic accuracy of these noninvasive methods for staging fibrosis. In addition, further clinical studies and animal experiments are required to investigate whether the occurrence rates are the same in the subjects that exhibit NAFLD, HBV, or HCV for the same period of time. Moreover, basic research about gene analysis may explain the mechanisms of the progress of fibrosis and the differences in disease in individuals with NAFLD.
